Skip to Content

Frequently Searched

Supported by

CAR T-Cell Therapy Directory

Published Date:

CAR T-cell therapies differ in their indications, dosing, treatment logistics, and monitoring needs. The CAR T-Cell Therapy Directory, featured in the Fall 2026 issue of Oncolytics Today, brings these details together in tables organized by disease state for convenient clinical reference.

Developed by Kelly Brunk, PharmD, MBA, BCOP; Madelyn Floysand, PharmD; and Thomas Peña, PharmD Candidate, the directory covers seven therapies across leukemia, lymphoma, and multiple myeloma. Explore indications, lymphodepleting regimens, manufacturing timelines, adverse events, and monitoring considerations, with information compiled as of September 1, 2026.

DOWNLOAD ARTICLE

Explore the Fall 2026 edition of Oncolytics Today

VIEW

Chart by Kelly Brunk, PharmD, MBA, BCOP, Senior Manager of Clinical Excellence at NCODA, Yorkville, Illinois, Madelyn Floysand, PharmD, Oncology, Advocacy, Health Policy & Equity Fellow at NCODA, Denver, and Thomas Peña, PharmD Candidate, University of Texas at Austin College of Pharmacy, Austin, Texas.

 

ALL, acute lymphoblastic leukemia; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; CI, confidence interval; CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GBS, Guillain-Barré syndrome; GGT, gamma-glutamyl transferase; HGBCL, high-grade B-cell lymphoma; HLH/MAS, hemophagocytic lymphohistiocytosis/macrophage activation syndrome; HSCT, hematopoietic stem cell transplantation; ICANS, immune effector cell-associated neurotoxicity syndrome; IEC-EC, immune effector cell-associated enterocolitis; IMiD, immunomodulatory drug; IQR, interquartile range; IV, intravenous; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; R/R, relapsed or refractory; SLL, small lymphocytic lymphoma.

1. Yescarta. Prescribing information. Kite Pharma, Inc; 2026. Accessed September 1, 2026. https://www.fda.gov/media/108377/download.

2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447.

3. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640- 654. doi:10.1056/NEJMoa2116133.

4. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X.

5. Tecartus. Prescribing information. Kite Pharma, Inc; 2026. Accessed September 1, 2026. https://www.fda.gov/media/140409/download

6. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347

7. Shah BD, Bishop MR, Al Malki MM, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a phase 2 multicentre single-arm trial. Lancet. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8

8. Kymriah. Prescribing information. Novartis Pharmaceuticals Corp; 2025. Accessed September 1, 2026. https://www.fda.gov/media/107296/download

9. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866

10. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980

11. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult patients with relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325-332. doi:10.1038/s41591-021-01622-0.

12. Aucatzyl. Prescribing information. Autolus Therapeutics; 2026. Accessed September 1, 2026. https://www.fda.gov/media/183463/download.

13. Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene autoleucel (obe-cel) for relapsed/refractory adult B-cell acute lymphoblastic leukemia: primary results of the FELIX study. J Clin Oncol. 2024;42(34):3990-4001. doi:10.1200/JCO.24.01183.

14. Breyanzi. Prescribing information. Bristol-Myers Squibb Company; 2026. Accessed September 1, 2026. https://www.fda.gov/media/145711/ download.

15. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0.

16. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem-cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10344):2367-2382. doi:10.1016/S0140-6736(22)01062-9.

17. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicenter, open-label, single-arm, phase 1-2 study. Lancet. 2023;402(10402):641-654. doi:10.1016/S0140-6736(23)01051-0.

18. Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in relapsed or refractory follicular lymphoma and marginal zone lymphoma: primary results from the TRANSCEND FL study. Nat Med. 2024;30(5):1399-1409. doi:10.1038/s41591-024-02986-x.

19. Abecma. Prescribing information. Celgene Corporation; 2025. Accessed September 1, 2026. https://www.fda.gov/media/147055/download.

20. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705- 716. doi:10.1056/NEJMoa2024850.

21. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Idecabtagene vicleucel or standard regimens in multiple myeloma. N Engl J Med. 2023;388(11):1002-1014. doi:10.1056/NEJMoa2213614.

22. Carvykti. Prescribing information. Janssen Biotech, Inc; 2025. Accessed September 1, 2026. https://www.fda.gov/media/156560/download.

23. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8.

24. San-Miguel J, Dhakal B, Yong K, et al. Ciltacabtagene autoleucel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379.